Form 4: Mersana Therapeutics Acquired, Executive's Holdings Converted

Mersana Therapeutics, Inc. completed its merger with Day One Biopharmaceuticals, Inc., converting executive Alejandra Carvajal's equity holdings into cash and contingent value rights.

Summary

• Mersana Therapeutics, Inc. (MRSN) has been acquired by Day One Biopharmaceuticals, Inc. (Parent) through a tender offer and subsequent merger, effective January 6, 2026.
• Alejandra Carvajal, SVP, Chief Legal Officer of Mersana Therapeutics, Inc., reported changes in her beneficial ownership due to this merger.
• Common stock shares were exchanged for an Upfront Cash Consideration of $25.00 per share, plus one non-tradeable contingent value right (CVR) per share.
• Each CVR represents the right to receive contingent milestone payments of up to an aggregate of $30.25 per CVR in cash.
• Stock options with an exercise price less than the Upfront Cash Consideration (Cash-Out Options) became fully vested, were cancelled, and converted into the right to receive the Offer Price minus their exercise price.
• Stock options with an exercise price equal to or greater than the Upfront Cash Consideration (OTM Options) became fully vested and exercisable for a limited period, then cancelled if not exercised.
• Restricted Stock Units (RSUs) were automatically cancelled and converted into the right to receive the Offer Price.

Sentiment

Score: 7

Explanation: The filing reports the mandatory conversion of equity holdings due to a completed merger, which provided shareholders with upfront cash and potential future contingent payments. This represents a definitive liquidity event for shareholders and a structured resolution for equity holders.

Positives

• The merger provided Mersana Therapeutics, Inc. shareholders with immediate liquidity through an Upfront Cash Consideration of $25.00 per share.
• Shareholders also received potential future upside through Contingent Value Rights (CVRs) of up to $30.25 per CVR.
• Certain stock options (Cash-Out Options) held by the reporting person became fully vested and were converted into cash consideration.

Negatives

• Stock options with an exercise price equal to or greater than the Upfront Cash Consideration (OTM Options) that were not exercised by the specified deadline were cancelled without any consideration.

Future Outlook

This filing primarily reports the completed merger transaction and its impact on the reporting person's equity holdings. It does not provide forward-looking statements or guidance regarding the future performance or strategic direction of the combined entity.

Industry Context

The acquisition of Mersana Therapeutics by Day One Biopharmaceuticals is a typical transaction within the biotechnology and pharmaceutical industry. The use of contingent value rights (CVRs) is a common mechanism in such mergers to bridge valuation gaps and allow selling shareholders to participate in the potential future success of clinical or regulatory milestones, particularly for companies with pipeline assets.

Comparison to Industry Standards

• The structure of the acquisition, involving an upfront cash payment combined with contingent value rights (CVRs), aligns with common practices in the biotechnology sector for companies with assets in various stages of development. This approach is often utilized when there is uncertainty regarding the future value of pipeline candidates, allowing for a risk-sharing mechanism.
• Specific comparable companies or projects are not detailed in this filing, but similar CVR structures have been observed in acquisitions of clinical-stage biotech firms, where milestone payments are tied to regulatory approvals or commercialization achievements.

Corporate Governance

Stakeholder Impact

• Shareholders of Mersana Therapeutics, Inc. received a combination of upfront cash and contingent value rights for their shares, providing immediate value and potential future payments.
• Employees holding stock options and restricted stock units, such as the reporting person, had their equity converted according to the merger terms, resulting in either cash payouts or cancellation depending on the option type and exercise status.

Key Dates

Keywords

Mersana Therapeutics, MRSN, Day One Biopharmaceuticals, merger, acquisition, Form 4, beneficial ownership, stock options, restricted stock units, CVR, contingent value rights, executive compensation